Novo Nordisk A/S: all 1,444 studies

Page 9 of 15. Open to participants first (108), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate Safety and Effectiveness in Patients of All Age Groups Excluding Less Than 12 Months Old Infants With Diabetes Mellitus in Routine Clinical Practice in KoreaCompletedNCT02779413
• A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 DiabetesCompletedNCT02773381Phase 1
• Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican PatientsCompletedNCT02773355
• A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes MellitusCompletedNCT02754817
• A Trial to Assess the Effects of Liraglutide on Gallbladder Emptying in Overweight and Obese Subjects.CompletedNCT02717858Phase 1
• A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 YearsCompletedNCT02696148Phase 1
• A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in JapanCompletedNCT02670213
• Investigating the Effectiveness of Tresiba® (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes MellitusCompletedNCT02662114
• A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®CompletedNCT02627287Phase 1
• Development of Pre-pregnancy Intervention to Reduce the Risk of Diabetes and PrediabetesCompletedNCT02617693Phase 4
• A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0143-0406 A 0.6 mmol/L in Subjects With Type 1 DiabetesCompletedNCT02612844Phase 1
• Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial ParticipantsCompletedNCT02608853
• A Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic ProfilesCompletedNCT02594033Phase 1
• Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)CompletedNCT02580032
• A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy SubjectsCompletedNCT02568306Phase 1
• Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT02568280Phase 1
• Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)CompletedNCT02568202
• Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once WeeklyCompletedNCT02557620Phase 1
• Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT02543879Phase 1
• Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes MellitusCompletedNCT02536859Phase 1
• Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A SubjectsCompletedNCT02490787Phase 1
• A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Insulin 320 in Healthy SubjectsCompletedNCT02479022Phase 1
• Trial to Compare NNC0123-0000-0338 in a Tablet Formulation and Insulin Glargine in Subjects With Type 2 Diabetes Currently Treated With Oral Antidiabetic TherapyCompletedNCT02470039Phase 2
• Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes MellitusCompletedNCT02392117
• Changing Diabetes in ChildrenTerminatedNCT02382757
• Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)CompletedNCT02321878
• A Survey on Low Blod Sugar Among Insulin-treated Patients With DiabetesCompletedNCT02306681
• Effect of Food on the Pharmacokinetics of NNC0123-0000-0338 in a Tablet Formulation in Healthy SubjectsCompletedNCT02304627Phase 1
• Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male SubjectsCompletedNCT02300844Phase 1
• Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in Daily PracticeCompletedNCT02255266
• Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Metformin and Digoxin in Healthy SubjectsCompletedNCT02249910Phase 1
• Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy SubjectsCompletedNCT02249871Phase 1
• Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy SubjectsCompletedNCT02243098Phase 1
• To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily LivesCompletedNCT02241694
• Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary BypassCompletedNCT02239146Phase 1
• Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male SubjectsCompletedNCT02235961Phase 1
• Investigating the Pharmacokinetics of Subcutaneous Injections With 1 mg/mL, 3 mg/mL, and 10 mg/mL Semaglutide Strengths and the Absolute Bioavailability of SemaglutideCompletedNCT02231684Phase 1
• A Survey on Hypoglycaemia Among Insulin-treated Patients With DiabetesCompletedNCT02230631
• Post Marketing Surveillance (PMS) Study of Ryzodeg™ (Insulin Degludec/Insulin Aspart) in Patients With Diabetes Mellitus in Routine Clinical Practice in IndiaCompletedNCT02230618
• A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes MellitusCompletedNCT02220296Phase 1
• A Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 DiabetesCompletedNCT02212067Phase 1
• Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionCompletedNCT02210871Phase 1
• Investigating Bioequivalence Between Single-dose Liraglutide Administered Subcutaneously With Two Different Pen-injectorsCompletedNCT02207348Phase 1
• To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in JapanCompletedNCT02207218
• A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With MetforminCompletedNCT02205528Phase 2
• Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy SubjectsCompletedNCT02172313Phase 1
• A Trial Investigating the Relationship Between Pharmacodynamic and Interstitial Concentration for Insulin Detemir and Human InsulinCompletedNCT02162407Phase 1
• A Trial to Assess the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Oral Semaglutide in Healthy Male Japanese and Caucasian SubjectsCompletedNCT02161588Phase 1
• Dose-escalation Trial of Anti-C5aR Antibody in Healthy SubjectsCompletedNCT02151409Phase 1
• A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered NNC0148-0287 (Insulin 287) in Subjects With Type 2 DiabetesCompletedNCT02148861Phase 1
• A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 DiabetesCompletedNCT02147431Phase 1
• A Trial to Assess the Pharmacokinetics, Pharmacodynamics, and the Safety and Tolerability of Semaglutide in Healthy Male Japanese and Caucasian SubjectsCompletedNCT02146079Phase 1
• A Randomised Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of Faster-acting Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT02131246Phase 1
• A Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba® (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in IndiaCompletedNCT02117622
• Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or LymphomaTerminatedNCT02110563Phase 1
• A Trial Investigating the Mechanism of Action of NNC0109-0012 (Anti-IL-20 mAb) Through Synovial Biopsies in Subjects With Rheumatoid Arthritis and an Inadequate Response to MethotrexateWithdrawnNCT02097264Phase 2
• Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male SubjectsCompletedNCT02094521Phase 1
• A Trial Comparing the Pharmacokinetic Properties of Faster-acting Insulin Aspart (FIAsp) After Different Injection Regions and Routes of Administration in Healthy SubjectsCompletedNCT02089451Phase 1
• Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male SubjectsWithdrawnNCT02084810Phase 1
• Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With PlaceboCompletedNCT02079870Phase 1
• A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in SwedenCompletedNCT02077946
• A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy SubjectsCompletedNCT02070510Phase 1
• A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh, Indonesia, Malaysia, Philippines, Sri Lanka and VietnamCompletedNCT02066766
• A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy SubjectsCompletedNCT02064348Phase 1
• Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male SubjectsCompletedNCT02060266Phase 1
• Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia ACompletedNCT02035384
• A Trial Investigating the Pharmacokinetic Properties of FIAsp in Children, Adolescents and Adults With Type 1 DiabetesCompletedNCT02035371Phase 1
• A Trial Investigating the Pharmacodynamic Response of Faster Acting Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT02033239Phase 1
• Influence of Semaglutide on Pharmacokinetics and Pharmacodynamics of Warfarin and Pharmacokinetics of Metformin in Healthy SubjectsCompletedNCT02022254Phase 1
• Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic ImpairmentCompletedNCT02016911Phase 1
• Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal FunctionCompletedNCT02014259Phase 1
• Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)CompletedNCT02005198
• A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 DiabetesCompletedNCT02003677Phase 1
• A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 DiabetesCompletedNCT01992588Phase 1
• Impact of Pain on Functional Impairment and Quality of Life in Adults With HemophiliaCompletedNCT01988532
• Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®CompletedNCT01984372
• Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy SubjectsCompletedNCT01978613Phase 1
• A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone DeficiencyCompletedNCT01973244Phase 1
• Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male SubjectsCompletedNCT01967589Phase 1
• Project to Update the Study of Congenital Haemophilia in SpainCompletedNCT01959555
• A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Sri LankaWithdrawnNCT01957592
• A Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0215-0384 Administered to Subjects With Moderate to Severe Rheumatoid ArthritisCompletedNCT01955603Phase 1
• GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes MellitusCompletedNCT01950650
• GAPP 2 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Type 2 Diabetes MellitusCompletedNCT01950637
• A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without InhibitorsCompletedNCT01949792Phase 1
• A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult SubjectsCompletedNCT01943084Phase 1
• A Trial Investigating the Pharmacokinetic Properties of FIAsp in Japanese Subjects With Type 1 DiabetesCompletedNCT01934712Phase 1
• A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in IndonesiaCompletedNCT01934686
• A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in MalaysiaCompletedNCT01934673
• A Trial Investigating the Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in a Tablet Formulation With Three Different Coatings in Healthy SubjectsCompletedNCT01931137Phase 1
• A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Subjects With Type 1 DiabetesCompletedNCT01924637Phase 1
• A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy SubjectsCompletedNCT01916174Phase 1
• Evaluation of Biomarker Expression in Diabetic and Healthy Subjects Over a One Year PeriodCompletedNCT01900834
• An International Non-interventional Cohort Study to Evaluate the Safety of Treatment With Insulin Detemir in Pregnant Women With Diabetes Mellitus. Diabetes Pregnancy RegistryCompletedNCT01892319
• Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in EuropeCompletedNCT01890993
• A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in BangladeshCompletedNCT01877200
• A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in JapanCompletedNCT01876745
• Bioequivalence Between Two Explorative Insulin Degludec Formulations and Between Two Explorative IDegAsp Formulations in Healthy SubjectsCompletedNCT01868581Phase 1
• Comparison of IDegAsp (Inclusive Three Explorative Formulations) With Insulin Degludec and Insulin Aspart Separately Injected in Subjects With Type 1 DiabetesCompletedNCT01868568Phase 1
• Safety, Pharmacokinetics and Pharmacodynamics of Two IDegAsp (One Explorative) Preparations and Two Insulin Degludec (One Explorative) Preparations in Japanese SubjectsCompletedNCT01868555Phase 1

← Novo Nordisk A/S overview and focus areas